Pratyush Pragyandipta Selected Research

Breast Neoplasms (Breast Cancer)

2/2024	Biochemical and in silico analysis of the binding mode of erastin with tubulin.
9/2023	Rational design of novel microtubule targeting anticancer drugs N-imidazopyridine noscapinoids: Chemical synthesis and experimental evaluation based on in vitro using breast cancer cells and in vivo using xenograft mice model.
2/2023	Development of 9-(N-arylmethylamino) congeners of noscapine: the microtubule targeting drugs for the management of breast cancer.
1/2022	In silico design of novel tubulin binding 9-arylimino derivatives of noscapine, their chemical synthesis and cellular activity as potent anticancer agents against breast cancer.
1/2022	Development of 1,3-diynyl derivatives of noscapine as potent tubulin binding anticancer agents for the management of breast cancer.
1/2021	Rational design, chemical synthesis and cellular evaluation of novel 1,3-diynyl derivatives of noscapine as potent tubulin binding anticancer agents.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pratyush Pragyandipta Research Topics

Disease

6	Breast Neoplasms (Breast Cancer) 02/2024 - 01/2021
6	Neoplasms (Cancer) 09/2023 - 01/2021

Drug/Important Bio-Agent (IBA)

7	Noscapine (Narcotine)IBA 09/2023 - 01/2021
6	TubulinIBA 02/2024 - 01/2021
2	Antitussive Agents (Antitussives)FDA Link 01/2022 - 01/2021
2	Antineoplastic Agents (Antineoplastics)IBA 01/2022 - 01/2022
2	AlkaloidsIBA 01/2022 - 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2023
1	Hormones (Hormone)IBA 09/2023
1	imidazopyridineIBA 09/2023